Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Adma Biologics (ADMA) Accumulated Depreciation & Amortization (2016 - 2025)

Adma Biologics' Accumulated Depreciation & Amortization history spans 13 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 3.9% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, up 3.9%, while the annual FY2025 figure was $8.0 million, 3.9% up from the prior year.
  • Accumulated Depreciation & Amortization reached $8.0 million in Q4 2025 per ADMA's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.0 million in Q4 2025 to a low of $1.1 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.4 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 283.33% in 2022, then tumbled 66.67% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $4.8 million in 2021, then soared by 33.33% to $6.4 million in 2022, then increased by 18.75% to $7.6 million in 2023, then rose by 1.32% to $7.7 million in 2024, then increased by 3.9% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Accumulated Depreciation & Amortization are $8.0 million (Q4 2025), $2.0 million (Q3 2025), and $4.0 million (Q2 2025).